Navigation Links
BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease
Date:12/16/2009

LYNBROOK, N.Y., Dec. 16 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease. Peyronie's disease is characterized by the presence of inelastic collagen on the shaft of the penis, which can distort an erection and make sexual intercourse difficult or impossible in advanced cases. The Phase 2b study, conducted by the Company's partner, Auxilium Pharmaceuticals, Inc., was designed to measure efficacy endpoints of improvement in penile curvature and improvement in patients' sexual quality of life using the Peyronie's disease Patient Reported Outcome (PRO) questionnaire. Overall, XIAFLEX demonstrated a statistically significant change compared to placebo at 36 weeks in both improvement in penile curvature (p=0.001) and the PRO Peyronie's disease bother domain (p=0.046). There was no statistically significant change in mean scores between XIAFLEX and placebo in the PRO penile pain, intercourse discomfort or intercourse constraint domains. XIAFLEX was well-tolerated and the most common treatment related adverse events in the Phase 2b study were consistent with adverse events reported in previous Peyronie's disease trials with XIAFLEX, which included injection site bruising, edema and pain.

"Peyronie's disease can be psychologically devastating and patients have very limited and undesirable treatment options today," commented Thomas L. Wegman, President of BioSpecifics. "We look forward to progress in the clinical program for XIAFLEX in Peyronie's disease in 2010."

In patients who received XIAFLEX, a mean improvement of 29.7% in penile curvature from baseline to 36 weeks was seen (54.4 to 38.2) vs. an 11.0% mean improvement in curvature seen in placebo patients (50.6 to 45.1); (p=0.001). In patients who received XIAFLEX, 60.5% of patients achieved the endpoint of at least a 25% reduction in angle of curvature vs. 25.0% of placebo patients achieving at least a 25% reduction in angle of curvature. In the PRO Peyronie's disease bother domain, the overall XIAFLEX treatment arm experienced a benefit in mean change in score from baseline to 36 weeks that was significantly better than the overall placebo arm benefit (p=0.046). Auxilium Pharmaceuticals Inc. expects to meet with the U.S. Food and Drug Administration (FDA) in the second quarter of 2010 to further discuss these results.

The Phase 2b study was a randomized, double-blind, placebo-controlled trial that was designed to assess the safety and efficacy of XIAFLEX when administered two times a week, every six weeks, for up to three treatment cycles (2 x 3). The study was conducted at 12 sites throughout the U.S., and 145 patients were monitored for 36 weeks following the first injection, with 109 patients receiving XIAFLEX as a series of intralesional injections and 36 receiving placebo (3:1 ratio) in the study. The treatment and placebo arms were also randomized to test for a benefit with the addition of penile modeling versus no modeling (1:1). Modeling refers to massaging of the plaque and is intended to maximize the enzymatic effect of the XIAFLEX injection in the plaque.

The trial was designed to measure the improvement in penile curvature and complete the validation of disease PRO, which measured four domains of patients' sexual quality of life over a period of 36 weeks: penile pain, Peyronie's disease bother, intercourse discomfort and intercourse constraint.

To qualify for the study, patients must have been diagnosed with Peyronie's disease for longer than six months, have stable disease, be able to maintain a rigid erection and have a penile contracture between 30 and 90 degrees. Patients were stratified by the degree of penile curvature (i.e. 30 degrees to 60 degrees versus 60 to 90 degrees).

About Peyronie's Disease

Peyronie's disease is characterized by the presence of inelastic collagen on the shaft of the penis, which can distort an erection and make sexual intercourse difficult or impossible in advanced cases. Significant psychological distress has been noted in sexually active patients with Peyronie's disease. Currently, there are no effective pharmaceutical therapies for this ailment.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's disease, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its partner Auxilium has announced the acceptance of the Biologic License Application and Priority Review by the FDA's Arthritis Advisory Committee for injectable collagenase XIAFLEX in the treatment of Dupuytren's disease, and on September 16, 2009, the Arthritis Advisory Committee unanimously recommended, by a vote of 12 to 0, that the FDA approve XIAFLEX for the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the ability of its partner Auxilium to obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's disease and Peyronie's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments it may receive; the amount of earn out payments it may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under the companies' license agreement for additional indications; the potential benefits of its existing license and development agreements; its estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company's Form 10-K for the year ended December 31, 2008 and the Form 10-Q for the quarter ended September 30, 2009 and any subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE BioSpecifics Technologies Corp.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
2. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
3. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies
6. Greenway Medical Technologies PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification
7. The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies
8. New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
9. Remote Technologies Improve Patient Care, Viable Alternative to Intensivist Shortage
10. Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology
11. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
(Date:4/27/2016)... April 27, 2016   Zillion Group ... health technology platform, which specializes in live video ... scalable digital products, Zillion enables companies to realize ... consumers to take control of their health. ... conferencing – including one-to-one, group and webcast scheduled ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published ... her enthusiasm for Botox and lip injections, which she underwent in order to feel ... Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily ... confront and deal with these stressors is to adopt a more healthful diet, but ... you. Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach ...
(Date:4/29/2016)... Sterling, VA (PRWEB) , ... April 29, 2016 ... ... Americans with student loans more flexibility in repaying their loans, more information about ... at a time when total outstanding student loan debt, including federal and private ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive ... to announce one of their physicians has been invited to be a featured speaker ... Family Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, ...
(Date:4/29/2016)... ... 2016 , ... The Gluten-Free Certification Program (GFCP), in partnership ... launch of the GFCP Scoop in response to consumer demand for ... GFCP Scoop site is to keep the gluten-free community updated about ...
Breaking Medicine News(10 mins):